Immunovant, Inc. (IMVT)
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Address
320 WEST 37TH STREET
NEW YORK, NY 10018
Founded
2018
Number of Employees
207
Website
http://www.immunovant.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)